Treosulfan as an effective second-line therapy in ovarian cancer

Gynecologic Oncology

Volumn 71, Issue 1, 1998, Pages 94-98

  Gropp, M ^a   Meier, W ^a   Hepp, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TREOSULFAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0032191382     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5103     Document Type: Article

References (31)

1. Kuhn W, Jänicke F, Pache L, Hölscher M, Schattenmann G, Schmalfeldt B, Anderl H, Schüle G, Dettmar P, Siewert J R, Graeff H. Development in the therapy of the advanced ovarian cancer FIGO III. Geburtshilfe Frauenheilkd. 53:1993;293-302.
2. Jänicke F, Hölscher M, Kuhn W, v. Hugo R, Pache L, Siewert J R, Graeff H. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 70:1992;2129-2136.
3. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J L. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
4. Meier W, Römisch M, Hepp H. Stellenwert der Rezidivchirurgie in der Behandlung des Ovarialkarzinoms. Geburtshilfe Frauenheilkd. 53:1993;30-34.
5. Segna R A, Dottino P R, Mandeli J P, Konsker K, Cohen C J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 11:1993;434-439.
6. Thigpen, J, T, McGuire, W, P, Hoskins, W, J, Brady, M, F, Paclitaxel: current and future role in epithelial ovarian cancer. (abstract) New directions in anti-cancer chemotherapy, 31.1.1995, Bristol-Myers-Squibb, 14, 15.
7. Du Bois A. Chemotherapie beim Platin-refraktären Ovarialkarzinom. Aktuelle Onkologie 92, Taxol. München. 1996;Zuckschwerdt-Verlag. p. 1-19.
8. Gore M E, Fryatt I, Wiltshaw E, Dawson T, Robinson B A, Clavert A H. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer. 60:1989;767-769.
9. Markman M, Hakes T, Reichman B, Lewis J L Jr., Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 10:1992;243-248.
10. Repetto L, Chiara S, Mammoliti S. Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecol Oncol. 39:1990;146-149.
11. Sutton G. Secondary therapy for epithelial ovarian cancer - 1994. Semin Oncol. 21:1994;4:32-36.
12. Tropé C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemother Pharm. 26:1990;45-47.
13. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trepé C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol. 47:1992;282-286.
14. Anderson B. Quality of life in progressive ovarian cancer. Gynecol Oncol. 55:1994;151-155.
15. WHO, WHO Handbook for Reporting Results of Cancer Treatment, 1979.
16. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
17. Pfleiderer A, Meerpohl H. Standard der Chemotherapie beim Ovarialkarzinom. Chirurg. 65:1994;1-5.
18. Guidozzi F. Living with ovarian cancer. Gynecol Oncol. 50:1993;202-207.
19. Trimble E, Adams J, Vena D, Hawkins M, Friedman M, Fisherman J, Christian M, Canetta R, Onetto N, Hayn R, Arbuch S. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to NCI treatment referral center 9103. J Clin Oncol. 12:1993;2405-2410.
20. Uziely B, Groshen S, Jeffers S, Morris M, Russell C, Roman L, Muderspach L, Muggia F. Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. Ann Oncol. 5:1994;8827-8833.
21. Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol. 12:1994;60-63.
22. Kavanagh J J, Treskosol D, De Leon G. Phase II study of prolonged oral etoposide in refractory ovarian cancer. Int J Gynecol Cancer. 5:1995;351-354.
23. Kühnle H, Achterrath W, Frischkorn R. Krankheitsorientierte Phase II Studie mit Etoposid (NSC 141540) bei cisplatin-refraktären Ovarialkarzinomen. Tumordiagn Ther. 5:1984;152-155.
24. Kühnle H, Lenaz L, Meerpohl H G. Etoposide in cisplatin-refractory ovarian cancer. Proc Am Soc Clin Oncol. 7:1988;527.
25. Kuhn W, Schmalfeldt B, Dose J, Pache L, Ulöm K, Freitag K, Jänicke F, Graeff H. Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Frührezidivs. Geburtshilfe Frauenheilkd. 56:1996;105-110.
26. Markman M, Hakes T, Reichman B. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol. 119:1992;55-57.
27. Marth C, Pointner E, Zeimet A G, Abfalter E, Kozza A, Windbickler G, Hetzel H, Dapunt O. The value of etoposide (VP-16) as salvage therapy in refractory ovarian cancer. Geburtshilfe Frauenheilkd. 53:1993;303-307.
28. de Wit R, van der Burg M EL, v.d. Gaast A, Logmans A, Stoter G, Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum containing chemotherapy. Ann Oncol. 5:1994;656-657.
29. Vermorken J B, Kobierska A, Chevallier F, Zanaboni F, Pawinski A, Bolis G. Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin. Proc Am Soc Clin Oncol. 14:1995;276 (abstract 772).
30. Sinha B. Topoisomerase inhibitors. Drugs. 49:1995;11-19.
31. Kudelka, A, Edwards, C, Freedman, R, et al., A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma, Proc ECCO, 7, 722.